Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

25 Nov 2021

Industry Update: Funding For Psychedelic Startups Hits Record Levels

The psychedelic medicine market has been taking a beating as of late, but despite this short-term pain the overall outlook continues to be strong....

By Jason Najum

Science

20 Nov 2021

New Study: Microdosing Related to Lower Anxiety and Depression

This week we received some encouraging scientific news that supports people’s claims about microdosing's benefits...

By Jason Najum

Finance

19 Nov 2021

A Look at Small Cap Psychedelic Firms: Part 3

Small cap firms offer interesting potential opportunities for investors, so to help you stay informed we’ve put together a list of some of the top small cap companies....

By Jason Najum

Culture

17 Nov 2021

Jada Pinkett Smith and Son Jaden Share Their Psychedelic Experiences

The family sat down for an episode of their award-winning Facebook Watch series: Red Table Talk....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

15 Nov 2021

MindMed Announces Financial Results and Business Highlights

Quarterly updates are important tools to not only stay updated on a company’s progress but to remind us that an absence of headlines doesn’t mean a lack of progress....

By Jason Najum

Breaking News, Finance

12 Nov 2021

Positive Industry News for Cybin and Others Post-Wonderland

As the psychedelic medicine industry emerges from its collective post-Wonderland afterglow, we find a stream of positive industry news waiting for us on our feeds....

By Jason Najum

Industry

9 Nov 2021

COMPASS Pathways Announces Positive Results From Groundbreaking Phase 2b Trial

The industry has been waiting for this....

By Jason Najum

Breaking News

5 Nov 2021

Breaking News: Bright Minds Gets NASDAQ Approval, Trading Begins Nov 8

It was just over a year ago when MindMed’s NASDAQ application announcement set the psychedelic medicine industry on fire....

By Jason Najum

Breaking News

4 Nov 2021

Breaking News: Detroit Decriminalizes Psychedelics

This week the citizens of Detroit voted to decriminalize psychedelics through a ballot initiative....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.